"Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), for the Treatment of Adults with Growth Hormone Deficiency (AGHD): Results of VITAL, an Open-Label, Dose-Finding, International, Phase 2 Study (NCT02526420)" by Beverly M.K. Biller

Selected Works of Samer Nakhle, MD, FACE

Article

Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), for the Treatment of Adults with Growth Hormone Deficiency (AGHD): Results of VITAL, an Open-Label, Dose-Finding, International, Phase 2 Study (NCT02526420)

99th Annual Meeting of the Endocrine Society (2017)

Beverly M.K. Biller, Harvard University
Daniela Rogoff, Versartis, Inc.
Trish Rice, Premier Research
Shelby A Young
R. William Charlton, Versartis, Inc.
Bert Bakker, Versartis, Inc.
Maria Koltowska-Häggström, Pfizer
Eric Humphriss, Versartis, Inc.
Timothy S Bailey, AMCR Institute Inc.
Kimvir Singh Dhillon, Therapeutic Research Institute of Orange County
Ken Ho, Princess Alexandra Hospital
Laurence Katznelson, Stanford University
Kylie McLachlan
Shlomo Melmed, Cedars-Sinai Medical Center
Samer Nakhle, Palm Medical Research
Duncan J Topliss, Alfred Health
Whitney W. Woodmansee, Mayo Clinic
Kevin C.J. Yuen, Swedish Neuroscience Institute
Martin Bidlingmaier, Klinikum der Universität München
Christian J Strasburger, Charité

Disciplines

Publication Date

April 1, 2017

Citation Information

Beverly M.K. Biller, Daniela Rogoff, Trish Rice, Shelby A Young, et al.. "Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), for the Treatment of Adults with Growth Hormone Deficiency (AGHD): Results of VITAL, an Open-Label, Dose-Finding, International, Phase 2 Study (NCT02526420)" 99th Annual Meeting of the Endocrine Society (2017)
Available at: http://works.bepress.com/samer-nakhle/14/